The way that pharmaceutical manufacturers and payers contract is evolving due to the turbulent economic landscape and the increasing costs of drugs available for different therapeutic areas.  With competitive therapies, payers have difficult decisions to make as to which drugs are reimbursed.  This increased pressure has caused manufacturers to become creative and innovative with their strategies to gain optimal market access and a competitive advantage.

As risk-sharing and innovative contracting is a growing trend in Europe, it is important to analyze and evaluate the effectiveness of these agreements, compare different country’s approaches to applying them and understand the concrete, measurable outcomes and their ramifications.  It is also important to closely assess these unique contracts and how they impact all stakeholders: pharma, payers, pharmacists, physicians and patients.

There are still many questions about these agreements: their future, their structure and the impact that they will have with the advancement of medicine.  This conference is designed to provoke thoughtful discussion and much-needed direction by industry experts, payers and colleagues that have seen success with the application of this risk-based model of achieving market access.

I.  Identify Best Opportunities for Applying Risk-Sharing and Innovative Contracting

• Are clear endpoints and goals for risk-sharing agreements always achievable?

• Differentiating between Financial Based and Outcomes Based Contracts

II. Collaborate with Key Stakeholders Involved in Developing Risk-Sharing and Innovative Contracting Agreements

• Panel bringing all stakeholders together to best develop these agreements

* Manufacturer Perspective
* Payer Perspective
* Government Perspective
* HTA Perspective
* Physician Perspective
* Pharmacy Perspective
* Patient Perspective

III. Hearing Case Studies of Influential Risk-Sharing Agreements Implemented—Benefits and Downfalls

Hear what some of our previous attendees had to say:

“CBI’s inaugural risk-sharing and innovative contracting models conference convened top-level decision makers from key stakeholders in a setting conducive to open and constructive dialogue.”
– Joshua Cohen, Ph.D., Senior Research Fellow, Tufts Center for the Study of Drug Development, USA

“Robust discussions on very relevant topics in risk-sharing agreements.  Excellent insights from industry experts — both payer and manufacturer”
– James Smith, Director Managed Markets, Shire Pharmaceuticals

For more information or to register, please contact the Center for Business Intelligence toll free by phone at 1-800-817-8601 or via e-mail at cbireg@cbinet.com.